LGALS3BP: A Potential Prognostic Biomarker Influencing Antitumor Immunity in Triple-negative Breast Cancer.

IF 3.5 4区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current medicinal chemistry Pub Date : 2025-01-20 DOI:10.2174/0109298673367980250101053748

Anqi Hu, Shuaikang Pan, Yuan He, XueRu Wang, Dong Qian, Xiaoyang Li

{"title":"LGALS3BP: A Potential Prognostic Biomarker Influencing Antitumor Immunity in Triple-negative Breast Cancer.","authors":"Anqi Hu, Shuaikang Pan, Yuan He, XueRu Wang, Dong Qian, Xiaoyang Li","doi":"10.2174/0109298673367980250101053748","DOIUrl":null,"url":null,"abstract":"Objective: LGALS3BP exhibits differential expression in various types of tumors. This study aimed to analyze its potential diagnostic and prognostic value in Triple- negative Breast Cancer (TNBC).Methods: We conducted a comprehensive analysis of LGALS3BP's differential expression and its association with patient survival outcomes using data from public databases. To further validate these findings, Immunohistochemistry (IHC) experiments were performed to confirm the differential expression of LGALS3BP protein in TNBC. Additionally, we also investigated the relationship among LGALS3BP, tumor immune infiltration, and drug sensitivity.Results: Results indicated LGALS3BP to be significantly upregulated in TNBC, with its high expression correlating with improved survival outcomes. Furthermore, LGALS3BP expression correlated with immune cell infiltration. Notably, high LGALS3BP expression may confer a greater likelihood of benefiting from immunotherapy.Conclusion: LGALS3BP may serve as a diagnostic and prognostic biomarker for TNBC.","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673367980250101053748","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: LGALS3BP exhibits differential expression in various types of tumors. This study aimed to analyze its potential diagnostic and prognostic value in Triple- negative Breast Cancer (TNBC).

Methods: We conducted a comprehensive analysis of LGALS3BP's differential expression and its association with patient survival outcomes using data from public databases. To further validate these findings, Immunohistochemistry (IHC) experiments were performed to confirm the differential expression of LGALS3BP protein in TNBC. Additionally, we also investigated the relationship among LGALS3BP, tumor immune infiltration, and drug sensitivity.

Results: Results indicated LGALS3BP to be significantly upregulated in TNBC, with its high expression correlating with improved survival outcomes. Furthermore, LGALS3BP expression correlated with immune cell infiltration. Notably, high LGALS3BP expression may confer a greater likelihood of benefiting from immunotherapy.

Conclusion: LGALS3BP may serve as a diagnostic and prognostic biomarker for TNBC.

查看原文本刊更多论文

LGALS3BP：影响三阴性乳腺癌抗肿瘤免疫的潜在预后生物标志物

目的：LGALS3BP在不同类型肿瘤中的表达存在差异。本研究旨在分析其在三阴性乳腺癌（TNBC）中的潜在诊断和预后价值。方法：利用公共数据库的数据，我们对LGALS3BP的差异表达及其与患者生存结果的关系进行了全面分析。为了进一步验证这些发现，我们进行了免疫组织化学（IHC）实验来证实LGALS3BP蛋白在TNBC中的差异表达。此外，我们还研究了LGALS3BP与肿瘤免疫浸润和药物敏感性的关系。结果：结果表明，LGALS3BP在TNBC中显著上调，其高表达与生存结果的改善相关。此外，LGALS3BP表达与免疫细胞浸润相关。值得注意的是，高LGALS3BP表达可能更有可能从免疫治疗中获益。结论：LGALS3BP可作为TNBC的诊断和预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current medicinal chemistry 医学-生化与分子生物学

CiteScore

8.60

自引率

2.40%

发文量

468

审稿时长

3 months

期刊介绍： Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.